This is advertising promotion
Ananda Developments (ANA: AXS), a UK investment company for medical cannabis that aims to be the UK’s leading provider of consistent, high-quality medical cannabis that also has zero carbon.
With the global market for legal cannabis expected to be worth $91.5 billion by 2028 according to Grand Review Research, the EU market is steadily growing and Prohibition Partners estimate it will be worth £2.7 billion by 2025, with the UK market worth £450 million. by 2025 according to Arcview’s The State of Legal Cannabis Markets, Eighth Edition.
The market has seen a 50% increase in the number of cannabis-related IPOs since 2020 with the amount raised in European public markets increasing by over 116.2%.
Mergers and acquisitions reached record levels in 2021 with the $7.2 billion acquisition of British bio-cannabis company GW Pharmaceuticals by mainstream drugmaker Jazz Pharmaceuticals. Venture capital now makes up over 40% of active capital in the market as valuations are growing and angel investors are priced according to European hemp investment ecosystem, produced in partnership with DLA Piper, Enexis, and Hannam & Partners.
The medical cannabis that patients can access in the UK is currently imported, and quality and consistency appear to be uneven. We will provide a British source for high quality flowers and oils with unique strains suitable for signs treated in the UK, and with chemicals that thrive in UK conditions.
“Patients and prescribing physicians can be confident they are receiving a consistent, high quality product in the UK that is cutting edge because it hasn’t traveled far, and hasn’t drained energy or transport costs coming from the other side of the world.” Melissa Sturges, CEO of Ananda Developments.
Ananda’s innovative approach aims to reduce the carbon footprint of production and create greater transparency of the product’s cannabis profile to the end consumer.
Ananda will use a consistent, reliable, low-cost natural season approach and use nearly £4 million in sunken research costs to grow cannabis that will produce nearly zero greenhouse gas emissions without the use of artificial light or heat.
Creating a green future for British medical cannabis
The Ananda cannabis growing site in the UK has been chosen for its ideal climatic conditions, and medicinal cannabis will be grown within multi-building structures, providing low daytime variation in temperatures.
In contrast to traditional greenhouse cultivation, multi-church structures are flexible, allowing precise airflow management to create constant temperature and humidity, low cost, clean and environmentally friendly operation, all in an industry increasingly under fire due to its high energy consumption.
The extraction technology used in the cultivation of medical cannabis will also help to preserve the whole cannabis and terpene coil using the non-solvent extraction technology.
The right time for the industry to grow
The UK legalized medical cannabis in November 2018 and since then the industry has grown steadily in the same way as other approved countries.
The acquisition of 50% of DJT Plants in June 2019 secured a 50/50 deal with experienced UK farmers who previously held Home Office licenses to grow medical cannabis for GW Pharmaceuticals, providing a fast track to growing medical cannabis first for research and eventually commercial.
In May 2021, DJT Plants Limited (currently Ananda’s 50% subsidiary) was granted a Home Office Schedule 1 license to grow >0.2% THC cannabis for research purposes. This research aims to grow 65 strains for use in large-scale research. After receiving this license, Ananda agreed to acquire the remaining 50% of DJT Plants Limited’s equity interest in Ananda, thereby making it entirely internal.
Ananda’s best-in-class team of horticultural/agricultural medical cannabis growers will collaborate with world-leading cannabis geneticist Dr. Didi Meri and his team at the Laboratory for Cancer Biology and Cannabis Research at the Technion Israel Institute of Technology to analyze and understand the conduct of research.
Scalability through lower capital spending and lower oil production will match demand and increase returns at the highest standards. Ananda’s business model attaches importance to a patient-led approach, listening to and catering to the patient’s needs to inform the development of its products and innovations.
Ananda seizes the unique opportunity to position itself at the forefront of cannabis supply in Europe and to provide the best quality, consistent cannabis flowers and oils, to the highest standards, while creating shorter supply chains to the UK and European markets.
disclaimer: This article was written by Ananda Developments and published by Involved under a commercial agreement. It is not a recommendation to buy or sell shares. Article originally appeared in . format Involved” Spotlight Report On November 25, 2021.
Release date: December 09, 2021